Targeting endoglin over-expressed in tumor neovasculature has been used for therapeutic purposes with anti-endoglin antibodies [16], endoglin-targeted radioimmunotherapy [17], and anti-endoglin antibody–containing ITs [18]. The gene discussed is ENG; the disease is neoplasm.